Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics

Modern Rheumatology

Volumn 20, Issue 1, 2010, Pages 40-45

  Kawashiri, Shin Ya ^a   Kawakami, Atsushi ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Aramaki, Toshiyuki ^a   Tamai, Mami ^a   Arima, Kazuhiko ^a   Ichinose, Kunihiro ^a   Kamachi, Makoto ^a   Yamasaki, Satoshi ^a   Nakamura, Hideki ^a   Origuchi, Tomoki ^a   Ida, Hiroaki ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

DAS28; Rheumatoid arthritis; TNF antagonist; Tocilizumab; Tuberculosis

Indexed keywords

ADALIMUMAB; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STROMELYSIN; TOCILIZUMAB; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS PERITONITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG RESISTANCE; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76649095646     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0235-4     Document Type: Article

References (14)

1. M Mihara K Kasutani M Okazaki A Nakamura S Kawai M Sugimoto, et al. 2005 Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int Immunopharmacol 5 1731 1740 10.1016/j.intimp.2005.05.010 1:CAS:528: DC%2BD2MXns1Wns7Y%3D 16102523 (Pubitemid 41116745)
2. N Nishimoto J Hashimoto N Miyasaka K Yamamoto S Kawai T Takeuchi, et al. 2007 Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 1162 1167 10.1136/ard.2006.068064 1:CAS:528:DC%2BD2sXhtVKltL7O 17485422 (Pubitemid 47309731)
3. N Nishimoto N Miyasaka K Yamamoto S Kawai T Takeuchi J Azuma, et al. 2009 Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 19 12 19 10.1007/s10165-008-0125- 1 1:CAS:528:DC%2BD1MXhsFKmsLk%3D 18979150
4. P Emery E Keystone HP Tony A Cantagrel R van Vollenhoven A Sanchez, et al. 2008 IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 67 1516 1523 10.1136/ard.2008.092932 1:CAS:528: DC%2BD1cXhtl2gsbbI 18625622
5. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 10.1002/art.1780310302 1:STN:280:DyaL1c7pt1Ohsg%3D%3D 3358796
6. M Mierau M Schoels G Gonda J Fuchs D Aletaha JS Smolen 2007 Assessing remission in clinical practice Rheumatology (Oxford) 46 975 979 10.1093/rheumatology/kem007 1:STN:280:DC%2BD2szhsVOjsw%3D%3D (Pubitemid 47062506)
7. FA Houssiau JP Devogelaer J Van Damme CN de Deuxchaisnes J Van Snick 1988 Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides Arthritis Rheum 31 784 788 10.1002/art.1780310614 1:STN:280:DyaL1c3ltFGisA%3D%3D 3260102 (Pubitemid 18171300)
8. R Madhok A Crilly J Watson HA Capell 1993 Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity Ann Rheum Dis 52 232 234 10.1136/ard.52.3.232 1:STN:280:DyaK3s3kvFejtw%3D%3D 8484679
9. JA Karlsson LE Kristensen MC Kapetanovic A Gülfe T Saxne P Geborek 2008 Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 47 507 513 10.1093/rheumatology/ken034 1:CAS:528:DC%2BD1cXmslKhtbw%3D
10. JL Flynn MM Goldstein J Chan KJ Triebold K Pfeffer CJ Lowenstein, et al. 1995 Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice Immunity 2 561 572 10.1016/1074-7613(95)90001-2 1:CAS:528:DyaK2MXmsFCnurY%3D 7540941
11. AG Bean DR Roach H Briscoe MP France H Korner JD Sedgwick, et al. 1999 Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin J Immunol 162 3504 3511 1:CAS:528:DyaK1MXhvV2ru7k%3D 10092807
12. CH Ladel C Blum A Dreher K Reifenberg M Kopf SH Kaufmann 1997 Lethal tuberculosis in interleukin-6-deficient mutant mice Infect Immun 65 4843 4849 1:CAS:528:DyaK2sXntlWitL4%3D 9353074
13. MF Doran CS Crowson GR Pond WM O'Fallon SE Gabriel 2002 Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2287 2293 10.1002/art.10524 12355475
14. D Lacaille DP Guh M Abrahamowicz AH Anis JM Esdaile 2008 Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis Arthritis Rheum 59 8 1074 1081 10.1002/art.23913 18668604